Malignant neoplasm of descending colon
ICD-10 C18.6 is a billable code used to indicate a diagnosis of malignant neoplasm of descending colon.
C18.6 refers to a malignant neoplasm located in the descending colon, which is part of the large intestine. Colorectal cancer, including cancers of the descending colon, is a significant health concern and is often diagnosed through screening methods such as colonoscopy, fecal occult blood tests, and imaging studies. The disease can present with symptoms such as changes in bowel habits, rectal bleeding, abdominal pain, and unexplained weight loss. Staging of colorectal cancer is crucial for determining the extent of disease and treatment options, typically classified using the TNM system (Tumor, Node, Metastasis). The presence of microsatellite instability (MSI) can indicate a specific subtype of colorectal cancer that may respond differently to certain therapies. Surgical approaches for treating malignant neoplasms of the descending colon often involve resection of the affected segment, which may include partial colectomy or total colectomy, depending on the tumor's size and location. Adjuvant therapies, including chemotherapy and radiation, may also be indicated based on the stage of the cancer and the patient's overall health.
Detailed pathology reports, treatment plans, and follow-up notes are essential.
Patients undergoing chemotherapy or radiation therapy for colorectal cancer.
Ensure accurate staging and treatment documentation to support coding.
Endoscopy reports, biopsy results, and imaging studies are critical.
Patients presenting with symptoms of colorectal cancer or undergoing screening.
Document findings from colonoscopies and any interventions performed.
Used when a patient undergoes surgical resection of the descending colon.
Operative report detailing the procedure and findings.
Oncology and Gastroenterology must ensure accurate coding of the procedure.
Microsatellite instability (MSI) is a condition of genetic hypermutability that can affect the prognosis and treatment options for colorectal cancer. Tumors with MSI may respond better to certain immunotherapies, making it crucial for treatment planning.
